Quote:

---

Ohm, is this a serious threat to Leronlimab's MASH potential?

---

It is possible that Terns pharma could get FDA approval for MASH if the 10% difference between fibrosis and fibrosis progression holds up with a liver biopsy in phase 3. With what we've shown so far we'll beat it and I suspect the conversion from white hepatocellular fat to brown (good) fat is a longer term process so our MDI-PDFF scores might improve.

I sent this to someone in a PM.

Quote:

---

Nothing out of the ordinary here. Noureddin is the director of the Houston Liver Institute at the Houston Methodist Hospital. Terns pharma tasked them as the lead site for their study so of course Noureddin would be involved in the findings. I'm sure he's not going to quit Houston Methodist because he's also our scientific advisor. That trial along with the dozens of other trials in MASH he's done will better inform our phase 3 trial design.

Tern's drug did have a better reduction in liver fat than our drug. But more important than fat reduction is fibrosis. In that regard they were around 10% and in the 350mg dose in our trial we hit 24%. I still think there was something screwy about the results in the 700mg dose in our trial and would really like to see the raw data.

---